论文部分内容阅读
研究了二乙基二硫代氨基甲酸二乙铵（ＤＤＤＣ）对低浓度Ｐｂ、Ｔｌ（Ｉ）的萃取条件。在此基础上，发展了ＤＤＤＣ－乙酸丁酯联合萃取法，从能量为２９－２２ＭｅＶ、流强≤２０μＡ的质子束辐照后的金属铊靶中制备￣（２０１）ＴＩＣＩ注射液。１８批总量为３．１８×１０￣（１０）Ｂｑ的制备工作表明，产品的质量满足美国药典要求。化学产率８４％±２％，分离时间２．５－３ｈ，还可用于￣（２０３）ｐｂ的制备。注射液的异常毒性合格，小鼠体内分布和家兔显像实验结果良好。完成了临床１２４例验证实验，心肌显像清晰，诊断效果良好，受试人无任何不良反应。产品已获得卫生部颁发的新药证书。
The extraction conditions of low concentration Pb, Tl (I) by diethylammonium dithiocarbamate (DDDC) were studied. On this basis, the DDDC-butyl acetate combined extraction method was developed to prepare ~ (201) TICI injection from a metal thallium target irradiated by a proton beam with an energy of 29-22 MeV and a flow strength of ≤ 20 μA. 18 batches of 3.18 × 10 ~ (10) Bq preparation work shows that the quality of the product to meet the United States Pharmacopoeia requirements. Chemical yield of 84% ± 2%, separation time 2.5-3h, can also be used for ~ (203) pb preparation. Abnormal toxicity of the injection of qualified, in vivo distribution in mice and rabbit imaging results were good. Completed clinical validation of 124 cases of experiments, myocardial imaging was clear, the diagnosis of good results, the subjects without any adverse reactions. Products have been issued by the Ministry of Health new drug certificate.